SEC Form 4 · accession 0001127602-17-019287
BIOCRYST PHARMACEUTICALS INC · BCRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas R Staab II
Officer — Senior Vice President and CFO
Period of report
May 22, 2017
Accepted (ET)
May 24, 2017 · 4:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882796
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 22, 2017 | M | 7,750 | $4.73 | A | 149,210 | D | |
| Common StockF1 | May 22, 2017 | F | 6,996 | $5.24 | D | 142,214 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Emp. Stock Option (Right to Buy) | $4.73 | May 22, 2017 | M | 7,750 | D | Mar 1, 2013 | Mar 1, 2022 | Common Stock | 7,750 | 4,000 | D |
Explanation of responses
- F1Shares of Common Stock delivered to the Company to satisfy payment of exercise price in connection with stock option exercise.